CatalystMarker
← board

BAYRY

Bayerdistress 2/10 · well-funded / low risk
$13.07-2%today-14% from 52w high
bayer.com87,757 employeesFounded 1863Leverkusen, GermanyDrug Manufacturers - General
Lead: Left Ventricular Systolic Dysfunction
Revenue
$13405M
Liquidity
$6660M
Runway
—
Shares 1y
—

Price & events

+1.5% over 6M
$9.88$12.53$15.19Jan 26Apr 26Jul 265.4M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-3.9%
1W
+19.5%
1M
+13.1%
3M
-0.1%
6M
+54.4%
1Y
+81.2%
2Y
-4.9%
5Y
-1.9%
All

Overview

Volume
1.10K
52 Week Range
$7.25 – $15.19
Float Shares
3.93B
% Held by Insiders
0.00%
% Held by Institutions
0.36%
RVOL
0.00x
Beta
0.83

Pipeline stages · 16 programs

BAY3723113
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-08-31
BAY2599023 (DTX201)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-09-15
BAY3498264
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-11
BAY2927088
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-02-03
BAY3375968, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-30
Finerenone (Kerendia, BAY94-8862)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-31
BAY3546828
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-08
Darolutamide (BAY1841788, Nubeqa)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-07-30
Sevabertinib, Pembrolizumab, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10-28
Medroxyprogesterone acetate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11-01
Show all 16 programs · 6 more ▾
Regorafenib (Stivarga, BAY73-4506)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04-27
Darolutamide, ADT
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-15
Darolutamide (Nubeqa, BAY1841788)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-26
BAY 3670549
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-27
225Ac-PSMA-Trillium (BAY3563254)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-26
AB-1005
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12-15

Pipeline · 23 trials · 23 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-08-31
Estimated 50%
readout ~2026-11-14
Phase 3BAY3723113Obstructive Hypertrophic Cardiomyopathy—active not recruiting
2026-09-15
Estimated 50%
readout ~2026-10-30
Phase 1/2BAY2599023 (DTX201)Hemophilia A—active not recruiting
2027-01-11
Estimated 50%
readout ~2027-02-10
Phase 1BAY3498264Advanced Solid Tumors Harboring KRAS G12C Mutation—recruiting
2027-02-03
Estimated 50%
readout ~2027-03-20
Phase 2BAY2927088Advanced Solid Tumors, HER2 Mutation—recruiting
2027-04-30
Estimated 50%
readout ~2027-05-30
Phase 1BAY3375968, PembrolizumabAdvanced Solid Tumors—active not recruiting
Show all 23 trials · 18 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2027-05-31
Estimated 50%
readout ~2027-08-14
Phase 3Finerenone (Kerendia, BAY94-8862)Chronic Kidney Disease, Proteinuria—recruiting
2027-06-08
Estimated 50%
readout ~2027-07-08
Phase 1BAY3546828Metastatic Castration-resistant Prostate Cancer—active not recruiting
2027-07-30
Estimated 50%
readout ~2027-10-13
Phase 3Darolutamide (BAY1841788, Nubeqa)Biochemically Recurrent Prostate Cancer—active not recruiting
2027-10-28
Estimated 50%
readout ~2028-01-11
Phase 3Sevabertinib, Pembrolizumab, CisplatinAdvanced Non-small Cell Lung Cancer, HER2 Mutation—recruiting
2027-11-01
Estimated 50%
readout ~2028-01-15
Phase 3Medroxyprogesterone acetateEndometrial Hyperplasia—recruiting
2028-04-27
Estimated 50%
readout ~2028-06-11
Phase 2Regorafenib (Stivarga, BAY73-4506)Solid Malignant Tumors—active not recruiting
2028-06-15
Estimated 50%
readout ~2028-07-30
Phase 2Darolutamide, ADTHigh-Risk Localized Prostate Cancer—recruiting
2028-06-26
Estimated 50%
readout ~2028-09-09
Phase 3Darolutamide (Nubeqa, BAY1841788)Cancer—active not recruiting
2028-07-27
Estimated 50%
readout ~2028-09-10
Phase 2BAY 3401016Alport Syndrome—recruiting
2028-11-26
Estimated 50%
readout ~2028-12-26
Phase 1225Ac-PSMA-Trillium (BAY3563254)Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression—recruiting
2028-11-28
Estimated 50%
readout ~2029-02-11
Phase 3Finerenone (Kerendia, BAY94-8862)Chronic Kidney Disease, Proteinuria, Children—recruiting
2028-12-15
Estimated 50%
readout ~2029-01-29
Phase 2AB-1005Parkinson Disease—not yet recruiting
2029-06-17
Estimated 50%
readout ~2029-08-01
Phase 1/2BAY 3713372MTAP-deleted Solid Tumors—recruiting
2029-07-27
Estimated 50%
readout ~2029-08-26
Phase 1BAY 3771249, CetuximabAdvanced/Metastatic Colorectal Adenocarcinoma—recruiting
2029-07-31
Estimated 50%
readout ~2029-08-30
Phase 1BAY 3547926, BAY 3547922, BAY 3713391Hepatocellular Carcinoma—recruiting
2029-11-30
Estimated 50%
readout ~2030-02-13
Phase 3Finerenone (Kerendia, BAY94-8862)Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)—recruiting
2030-05-16
Estimated 50%
readout ~2030-06-30
Phase 2BAY 3670549Atrial Fibrillation—not yet recruiting
2030-12-30
Estimated 50%
readout ~2031-03-15
Phase 3Finerenone (Kerendia, BAY94-8862)Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)—recruiting

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $15 (+16% upside) · 4 analysts
  • no recent rating changes

Competitors — Left Ventricular Systolic Dysfunction

  • MRKMerck & Co., Inc.$318.8B · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.